Veracyte: Tina Nova, Stephane Debono, Giulia Kennedy
Veracyte has appointed Tina Nova as president of its US CLIA business, Stephane Debono as general manager of the company’s in vitro diagnostics and EMEA organizations, and Giulia Kennedy as its global chief scientific officer and chief medical officer.
In her role, Nova will lead market development, product marketing, payer reimbursement, sales, and operations for all diagnostic tests that are performed in the company’s US laboratories. Nova served most recently as Veracyte’s general manager of thyroid and urologic cancers. She was CEO of Decipher Biosciences prior to Veracyte’s March 2021 acquisition of that company.
Debono will oversee the development, manufacturing, market access, sales, and marketing of the company's IVD tests on the nCounter Analysis System to laboratories in global markets. He previously served as Veracyte's general manager for the immunoscore assay and international diagnostics operations. He was also deputy CEO of HalioDx prior to its acquisition by Veracyte in August 2021.
In her expanded role, Kennedy will oversee a worldwide team of research and development, medical affairs, data science, and clinical affairs professionals. She joined Veracyte in 2008, serving most recently as chief scientific officer and chief medical officer.